Skip to content
value.today

Provention Bio, Inc.

🇺🇸 Lebanon, New Jersey, USABiotechnologyFounded 2016
Total raised
$28 M
1 round on record
Latest round
$28 M
Apr 2017
First round on record
Apr 2017
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Provention Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2017$28 MNo. 1$10 to $50 million

Provention Bio, Inc.: Raise no. 1, Apr 2017

Investors in this round

158 investors had bought by the notice of May 4, 2017: 158 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Provention Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $30 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,396,850
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ashleigh Palmer · Executive Officer, Director
  • Anthony DiGiandomenico · Director
  • Cameron Gray · Director
  • Francisco Leon, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states
  • MDB Capital Group, LLC (CRD 42677) · Dallas, TexasSold in AL, AZ, CA, CO, CT, FL, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, NJ, NV, NY, OH, OK, OR, PA, RI, TX, UT, VA, VT, WA, WI

Remarks in the notice

  • On fees: “Excludes value of warrants to purchase up to 558,740 shares of Series A Preferred Stock.”
  • On the amounts: “Offering is closed.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3. Two Directors are principals of MDB and will receive a portion of the fees paid to MDB.”

Signed by Ashleigh Palmer, President. Source: SEC Form D, newest notice filed May 4, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Provention Bio, Inc. chose not to state its revenue in its newest notice of a funding round (May 2017).

    SEC Form D · May 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2017

That is all the official record says: Provention Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Provention Bio, Inc.
InvestorKindAmountRoundRoleSource
Johnson & Johnson Development Corp Et AlCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Peter A. AppelPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 158 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Provention Bio, Inc.
NameRoleNamed in
Ashleigh PalmerExecutive officerMay 2017
Anthony DiGiandomenicoDirectorMay 2017
Ashleigh PalmerDirectorMay 2017
Cameron GrayDirectorMay 2017
Francisco Leon, M.D.DirectorMay 2017